Boston Scientific Corporation BSX
Regular-session close
After hours · Nov 20, 7:52 PM ET
- YTD
- -55.97%
- 1 year
- -56.54%
5D -2.71 (-6.05%)
- Market cap
- 60.85B
- Revenue (ttm)
- 21.07B
- Profit margin
- 16.62%
- EPS (ttm)
- 2.37
- Shares out
- 1.45B
- P/E ratio
- 17.71
- Forward P/E
- 13.43
- YTD return
- -55.97%
- 1-year return
- -56.54%
- 50-day average
- 43.86
- Volume
- 15.23M
- Avg volume
- 19.51M
- Open
- 42.77
- Previous close
- 42.99
- Day's range
- 41.92 – 43.22
- 52-week range
- 41.58 – 101.58
- Beta
- 0.58
- Analysts
- Buy
- Price target
- 49.60 (+18.1%)
- Earnings date
- Feb 3, 2027
Key statistics
- 200-day average
- 53.25
- Enterprise value
- 73.90B
- PEG ratio
- 0.73
- Price / sales
- 2.89
- Price / book
- 2.38
- Revenue growth
- 1.40%
- Free cash flow
- 2.49B
- Total cash
- 609.00M
- Total debt
- 11.95B
- Return on equity
- 14.12%
- Short % of float
- 2.43%
Fundamental scorecard
17 of 25 checks passed on BSX’s reported financials
17of 25 checks passed
- Value 5 of 5
- Growth 5 of 5
- Profitability 4 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 41.00
- Target (mean)
- 49.60
- Target (high)
- 60.00
- Strong buy5
- Buy14
- Hold12
- Sell0
- Strong sell0
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 0.77579.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 0.78 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.727 | 0.73 | 0.00 | +0.41% |
| Jul 29, 2026 | Jun 30, 2026 | 0.835 | 0.86 | +0.03 | +2.99% |
| Apr 22, 2026 | Mar 31, 2026 | 0.788 | 0.80 | +0.01 | +1.52% |
| Feb 4, 2026 | Dec 31, 2025 | 0.781 | 0.80 | +0.02 | +2.43% |
| Oct 22, 2025 | Sep 30, 2025 | 0.714 | 0.75 | +0.04 | +5.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | TD Cowen | down | Buy | Hold |
| Oct 30, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 29, 2026 | Jefferies | down | Buy | Hold |
| Oct 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 29, 2026 | Bernstein | main | Outperform | Outperform |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bostonscientific.com
News
Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes
Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years
BSX's Weak Solvency and Cash Conversion Raise Financing Risk
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
Boston Scientific Corporation $BSX Position Reduced by AlTi Global Inc.
Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?
108,682 Boston Scientific Corporation $BSX Shares Bought by Aberdeen Group plc
Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years TD Cowen Downgrades Boston Scientific to Hold, Lowers Price Target to $46
Your note
Sign in to keep a note on BSX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRENNAN DANIEL J | Chief Financial Officer | Sale | Feb 18, 2025 | 225,808 |
| BROWN VANCE R | General Counsel | Conversion of Exercise of derivative security | Feb 12, 2026 | 54,244 |
| BUTCHER ARTHUR C | Officer | Conversion of Exercise of derivative security | Apr 30, 2026 | 77,115 |
| CARRUTHERS WENDY | Officer | Sale | Dec 1, 2024 | 29,308 |
| FITZGERALD JOSEPH MICHAEL | Officer | Conversion of Exercise of derivative security | Feb 12, 2026 | 219,141 |
| LUDWIG EDWARD J. | Director | Purchase | Jul 30, 2026 | 30,359 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.66% | 125,556,119 | 5.28B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.55% | 94,909,006 | 3.99B | Sep 29, 2026 |
| State Street Corporation | 4.64% | 67,322,516 | 2.83B | Sep 29, 2026 |
| Primecap Management Company | 4.04% | 58,624,997 | 2.47B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 3.13% | 45,388,381 | 1.91B | Sep 29, 2026 |
| Massachusetts Financial Services Co. | 2.97% | 43,054,393 | 1.81B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.26% | 47,181,284 | 1.98B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.66% | 38,518,788 | 1.62B | Jun 29, 2026 |
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 2.13% | 30,831,039 | 1.30B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 19,310,588 | 812.01M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 18,834,144 | 791.98M | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.23% | 17,894,864 | 752.48M | Sep 29, 2026 |
